On Thursday, Sept. 1, 2011, Ronald DePinho, M.D., began his presidency of MD Anderson Cancer Center. Here he shares his plans for his tenure as...
On Thursday, Sept. 1, 2011, Ronald DePinho, M.D., began his presidency of MD Anderson Cancer Center. Here he shares his plans for his tenure as president. DePinho is internationally recognized for basic and translational research in cancer, aging and age-associated degenerative disorders. He's the fourth full-time president of MD Anderson.
DePinho succeeds John Mendelsohn, M.D., who remains on MD Anderson faculty, returning to clinical and translational research as co-director of a new Institute for Personalized Cancer Therapy.
DePinho said in a Sept. 1 message to MD Anderson employees, "To eliminate cancer around the world -- what could be a more clear and noble mission? I intend to focus on where the greatest new opportunities lie for us, especially in basic science, in science-driven clinical care, and in education. And I will help you build upon the expertise, compassion and quality of our immense and unmatched clinical operation. I also will not shrink from the task of preparing MD Anderson for continued achievement in a challenging economic climate and era of health care reform."